Feb. 4, 2026-- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026. Dr. Sumit Sharma, retina and uveitis specialist at the Cole Eye Institute, will present first-time end-of-study clinical results, including Week 24 data, from the Phase 1b

Bristol Myers Squibb (NYSE: BMY) today announced they have teamed up with renowned goalkeeper and sports commentator Kasey Keller, who is publicly sharing his personal experience with non-Hodgkin lymphoma (NHL) for the first time. His story details a long and challenging treatment journey that ultimately led him to Breyanzi® (lisocabtagene maraleucel; liso-cel), a personalized CD19-directed CAR T cell therapy made from a patient’s own T cells and administered as a one-time infusion*. Through thi

Long known for manufacturing generics, vaccines and small-molecule drugs, India is attempting to shift its focus to the development of biologics and biosimilars. Over the last decade-plus, China has become a booming biopharma innovator thanks in part to a big boost from its government.Now the question is, can its neighbor to the south, India, make a similar advancement?Long known for manufacturing generics, vaccines and small-molecule drugs, India is attempting to shift its focus, with

Repertoire Immune Medicines has collaborated with Eli Lilly and Company to develop tolerising therapies to treat several autoimmune diseases. The partnership will focus on creating treatments intended to restore immune homeostasis and deliver durable remission for patients, avoiding the generalised immune suppression associated with existing therapies. Under the agreement, Repertoire will lead partnership activities up to the selection of development candidates, using its T cell receptor-epito

Biosion, Inc. (“Biosion”), a global, clinical-stage biotechnology company developing innovative antibody-based therapeutics, today announced that the first patient has been dosed in a Phase 1a/1b Investigator-Initiated Trial (IIT) evaluating BSI-082, a highly differentiated, fully human anti-SIRPα monoclonal antibody. The study is sponsored by and being conducted at the Mays Cancer Center, a National Cancer Institute (NCI)-designated Cancer Center and part of The University of Texas at San Anton

Feb. 03, 2026 -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will present new safety and efficacy data from the GA Depot Phase II study in primary progressive multiple sclerosis (PPMS) at the ACTRIMS Forum 2026 Conference, to take place February 5-7, 2026, in San Diego, CA. GA Depot is a long-acting injection version of the approved Glatiramer Acetate (GA, commercially

Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful efficacy and a significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy (IIM) Interim readout expected in 2H 2026 Feb. 03, 2026 -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced it had dosed the first patient in the Phase 2/3 IIMPACT

GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to extend cash runway through Q4 2026 Feb. 03, 2026 -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK

Feb. 3, 2026 -- Imbed Biosciences, a leader in advanced synthetic antimicrobial and tissue regeneration solutions, today announced a strategic investment from BioLab Holdings Inc. This investment is set to significantly expand Imbed Biosciences' reach within the US market, particularly in the MD office setting, and accelerate the development of its proprietary SAM™ Antimicrobial Technology platform to minimize wound care complications. "The strategic investment from BioLab Holdings marks a pivo

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Biogen’s litifilimab (BIIB059) for cutaneous lupus erythematosus (CLE), a chronic autoimmune skin condition. This designation aims to expedite the development and review of medicines for serious conditions. The FDA based its decision on comprehensive data, including findings from the Phase II LILAC study. Results from this trial indicated that litifilimab reduced skin disease activity in patients with CLE